华峰制药品牌怎么样 申请店铺

我要投票 华峰制药在医疗器械行业中的票数:649 更新时间:2026-02-15
华峰制药是哪个国家的品牌?「华峰制药」是 河南华峰制药有限公司 旗下著名品牌。该品牌发源于河南省濮阳市,由创始人娄 *在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力华峰制药品牌出海!将品牌入驻外推网,定制华峰制药品牌推广信息,可以显著提高华峰制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

华峰制药怎么样

河南华峰制药有限公司是2000年5月经国家有关部委批准成立的股份制企业,现有资产5000万元, 厂区占地面积3万平方米,建筑面积2万平方米,占地62亩的二期工程正在筹建中。公司拥有各类高、中级技术人员200余人,专业营销人员100余人。公司地处园林城、卫生城、文明城、旅游城濮阳市高新技术产业开发区。西有濮阳的绿色庄园、濮上园等城市标志性旅游景点,东临南北走向的城市绿化森林,环境幽雅,交通便利 。

河南华峰制药有限公司以开发治疗骨病系列药品为主,承担着国家治疗骨病骨伤研发药品的项目,目前拥有生产国药准字号丸剂、酒剂及膏药等六个剂型共20多个品种, 形成了具有传统中医药生产销售与临床推广为一体的经营新格局,公司以开发骨病治疗药品为主,承担着国家治疗骨病研究的项目,公司自行研制生产的“娄峰”牌正骨膏、治伤消瘀丸、风湿骨病丸、祛风湿膏、骨痛药酒等,以其品质及适应性赢得了广大用户的认可,在医院专科专病建设领域树立了品牌。公司产品市场销售及医疗服务网络涉及东北地区、北京、山东、山西、安徽、江苏、上海等省市700多家医疗单位,创出了一条医疗服务和药品销售相结合的经营新模式,形成了区域拓展广阔的销售网络。

华峰公司将发展领域定位于人类健康产业,即中医药产业。专注于骨科病等病症的名优中成药,实施名牌战略,中药现代化和产业化的接轨,高度重视以市场为导向,具有前沿技术的研发能力的培育,完善以顾客为导向的营销战略,保障在行业中保持优势的竞争地位。华峰核心竞争力源于企业核心技术能力、应变能力、组织协调能力和企业影响力。华峰注重企业文化的建设借以形成能力出众、卓识创新的人才群体,打造高水准的华峰营销模式,不断改进华峰的管理和生产模式,提高华峰品质,以形成华峰的市场竞争力。

进入新世纪,经济全球化、全球信息化、知识经济新时代已经来临,它对公司现有的生产方式、生活方式、思维方式、管理方式等都将产生重大影响,必将引发企业管理上的新一轮创新性的革命。华峰全体员工将认清形势,持续不断地开展观念创新、知识创新、管理创新、市场创新、机制创新、技术创新、质量创新、产品创新,以求真、务实、创新的精神和干劲,保持企业稳健、持续发展,做行业先锋,创世纪品牌。

成熟的技术,优良的设备,科学的管理,使河南华峰制药有限公司成为研发与生产治疗骨病系列药品的优势企业,在全国地区的中药制药现代化进程中焕发出无限生机。


Henan Huafeng Pharmaceutical Co., Ltd. is a joint-stock enterprise established in May 2000 with the approval of the relevant ministries and commissions of the state. The current assets are 50 million yuan, the plant covers an area of 30000 square meters, the building area is 20000 square meters, and the second phase project covering 62 Mu is under preparation. The company has more than 200 high and intermediate technical personnel and more than 100 professional marketing personnel. The company is located in the park city, health city, civilization city, tourism city Puyang high tech Industrial Development Zone. In the west, there are the Green Manor of Puyang, the park of pushangyuan and other urban landmark tourist attractions. In the East, there is the North-South urban green forest, with elegant environment and convenient transportation. Henan Huafeng Pharmaceutical Co., Ltd. is mainly engaged in the development of a series of drugs for the treatment of osteopathy, and undertakes the national research and development of drugs for the treatment of osteopathy and osteopathy. At present, it has produced more than 20 varieties of six dosage forms, such as Guoyao Zhun brand pills, liquors and plasters, forming a new business pattern with the integration of traditional Chinese medicine production and sales and clinical promotion. The company focuses on the development of drugs for the treatment of osteopathy The company has undertaken the national research project of bone disease treatment. The company has developed and produced "Loufeng" brand bone paste, zhishangxiaoyu pill, Fengshi bone disease pill, Qufengshi ointment, bone pain medicine liquor, etc., which have won the recognition of the majority of users for their quality and adaptability, and established a brand in the field of hospital specialized disease construction. The company's product market sales and medical service network involve more than 700 medical units in Northeast China, Beijing, Shandong, Shanxi, Anhui, Jiangsu, Shanghai and other provinces and cities. It has created a new business model combining medical service and drug sales, and formed a wide regional sales network. Huafeng company will focus on the development of human health industry, that is, traditional Chinese medicine industry. Focus on famous and excellent Chinese patent medicines for orthopedic diseases, implement the famous brand strategy, integrate the modernization and industrialization of traditional Chinese medicine, attach great importance to the cultivation of market-oriented, cutting-edge technology research and development ability, improve customer-oriented marketing strategy, and ensure the competitive position in the industry. The core competitiveness of Huafeng comes from the core technology ability, adaptability, organization and coordination ability and enterprise influence. Huafeng attaches great importance to the construction of corporate culture so as to form a talent group with outstanding ability and outstanding innovation, build a high-level marketing mode, constantly improve the management and production mode of Huafeng, improve the quality of Huafeng, and form the market competitiveness of Huafeng. In the new century, the new era of economic globalization, global information and knowledge economy has come. It will have a significant impact on the company's existing production mode, life style, thinking mode, management mode, etc., and will inevitably lead to a new round of innovative revolution in enterprise management. All staff of Huafeng will recognize the situation, continuously carry out concept innovation, knowledge innovation, management innovation, market innovation, mechanism innovation, technology innovation, quality innovation and product innovation, keep the enterprise steady and sustainable development, be the industry leader and create century brand with the spirit and drive of truth-seeking, pragmatic and innovation. With mature technology, excellent equipment and scientific management, Henan Huafeng Pharmaceutical Co., Ltd. has become an advantageous enterprise in R & D and production of series drugs for treating bone disease, which is full of infinite vitality in the process of modernization of traditional Chinese medicine in the whole country.

本文链接: https://brand.waitui.com/e4731c9c9.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

星巴克计划今年在韩国新开至少100家门店

星巴克韩国公司周日表示,预计今年将在韩国开设至少100家新门店,继续在亚洲第四大经济体稳步扩张。星巴克于1999年进入韩国市场,截至2025年底在韩国拥有2115家门店,使其成为继美国(16911家)和中国(8011家)之后,星巴克在全球门店数量排名第三的市场。星巴克目前在日本拥有2105家门店。(新浪财经)

21分钟前

法国扩大婴儿配方奶粉调查,雀巢与达能等公司列入名单

法国巴黎检察官办公室当地时间2月13日声明称,已针对雀巢公司、达能集团、拉克塔利斯集团及其他两家公司分销可能受污染的婴儿配方奶粉展开调查,此次调查可能涉及“以危害人类健康的商品进行欺骗”的指控,最高可判处七年监禁和375万欧元的罚款,此次调查由检察官办公室公共卫生部门牵头,旨在查明相关公司是否因违反安全规定、未能召回受污染产品及其他违规行为而对危及生命负有责任。(界面)

21分钟前

2025年韩国证券公司净利润突破10万亿韩元,创历史新高

周日公布的行业数据显示,2025年韩国主要券商受益于当地股市的牛市行情,盈利创下历史新高。27家证券公司的净利润总额据估计达到10.23万亿韩元(约合70.3亿美元),较上年的6.97万亿韩元大幅增长。韩国综合股价指数(KOSPI)去年上涨了超过75%,今年迄今也上涨了约30%。(新浪财经)

21分钟前

2026年春节档票房破3亿

36氪获悉,据猫眼专业版数据,2026年春节档档期总票房破3亿,《飞驰人生3》《惊蛰无声》《镖人:风起大漠》分列2026年春节档票房榜前三。 ​​​

21分钟前

老庙黄金足金饰品14日报1565元/克

当地时间13日,美国CPI数据公布后,市场对美联储降息的概率预期上升,美元指数回落,支撑贵金属资产吸引力,黄金白银再度反弹。14日,国内品牌金饰价格随之上调,查询到,周生生足金饰品报1551元/克,较前一日1524元/克单日上涨27元;老庙黄金足金饰品报1565元/克,较前一日1529元/克单日上涨36元。(中新经纬)

21分钟前

本页详细列出关于华峰制药的品牌信息,含品牌所属公司介绍,华峰制药所处行业的品牌地位及优势。
咨询